



UCLA SCHOOL OF MEDICINE

DEPARTMENT OF MOLECULAR AND MEDICAL PHARMACOLOGY
LABORATORY OF STRUCTURAL BIOLOGY AND MOLECULAR MEDICINE (DOE)

DR. MICHAEL E. PHELPS
Norton Simon Professor
Chair, Department of Molecular and Medical Pharmacology
Associate Director, Laboratory of Structural Biology and Molecular Medicine
Chief, Division of Nuclear Medicine

Box 951735
Los Angeles, CA 90095-1735
Phone: (310) 825-6539
Fax: (310) 825-6267
mphelps@mednet.ucla.edu
World Wide Web: <http://www.nuc.ucla.edu>

August 14, 2003

Steve E. Phurrough, MD, MPA
Acting Director, Coverage and Analysis Group
Office of Clinical Standards and Quality
Chief Medical Officer, Centers for Medicare & Medicaid Services
Director, Division of Medical & Surgical Services
7500 Security Blvd.
Baltimore, MD 21244


Dear Dr. Phurrough:

I have enclosed a new and more restricted coverage request for the use of Positron Emission Tomography (PET) for assisting physicians in the diagnosis of mild to moderate Alzheimer's Disease, than submitted to CMS on October 12, 2001. Well-defined patient selection criteria are included along with the evidence to support this request. The patient selection criteria have been developed from a consensus of some of the country's leading experts in the care and research associated with Alzheimer's Disease.

The request is being submitted by a broad range of professionals involved in clinical care and research devoted to the welfare of patients with Alzheimer's disease and related dementias. These individuals come from a wide variety of clinical care environments, research settings, educational institutions, and professional organizations. These individuals and their affiliations are listed at the bottom of the coverage request.

We appreciate your review and decision on this request.

Warm regards,


Dr. Michael E. Phelps

cc: Dr. Sean Tunis, Medical Director, CMS
The Honorable Tommy Thompson, Secretary, Health & Human Services

12 August 2003

Coverage request for positron emission tomography (PET) used in the evaluation of Alzheimer's disease and related dementias

This coverage request represents a more restricted and defined coverage request than submitted to CMS on October 12, 2001, that we believe is well supported by the evidence provided in this proposal.

The signatories below -- representing a broad range of professionals involved in clinical care and research devoted to the welfare of patients with Alzheimer's disease and related dementias, operating in a wide variety of clinical and care environments, research settings, educational institutions, and professional organizations -- submit this request in unanimous support for coverage of the use of PET for the evaluation of dementia under the explicitly defined conditions listed below. A summary of the scientific literature most pertinent to the request and its supporting rationale follows.

Request for coverage

Medicare Coverage is requested to include reimbursement for brain positron emission tomography (PET) performed with the radiopharmaceutical [F-18]fluorodeoxyglucose (FDG) to distinguish patients with Alzheimer's disease (AD) from those with other causes of symptoms confounding the diagnosis of dementia, or to assist with the diagnosis of early dementia in beneficiaries for whom the differential diagnosis includes one or more kinds of neurodegenerative disease (e.g., AD and frontotemporal dementia), in cases for which the referring physician's medical record documents that all of the following criteria have been met:

- 1) patient has A) gradually progressive decline in one or more cognitive domains, and/or B) cognitive impairment representing a change from patient's normal level of functioning which includes: (i) memory loss, (ii) other cognitive impairment, and (iii) functional impairment;
- 2) patient has undergone comprehensive history and physical including neurological examination (per American Academy of Neurology guidelines; Knopman et al., 2001), common screening laboratory tests, and if indicated, structural imaging with CT or MRI, which does not provide explanation for cognitive impairment or symptoms, or which has not resulted in treatment of potentially reversible cause(s) of dementia that has restored patient to normal state of cognition;
- 3) As determined by a structured assessment of mental status, patient is documented to not suffer from severe dementia at the time of PET scan (such as an MMSE score of not less than or equal to 10), but is impaired sufficiently to warrant a neuroimaging evaluation, meeting criteria set forth in sub-clause 1);
- 4) brain SPECT scan has not been obtained for same indication, after the date of the CMS coverage decision for PET and AD;
- 5) diagnosis of dementia will have a specific impact on the care of patient and on major life planning decisions for patient, as made by patient, family or caregiver; and

- 6) physician has evidence from a collateral source or a serial examination that cognitive impairment has been present for six months prior to ordering a PET scan.

REFERENCES

- Albin RL, Minoshima S, D'Amato CJ, Frey KA, Kuhl DA, Sima AAF. Fluoro-deoxyglucose positron emission tomography in diffuse Lewy body disease. *Neurology* 1996;47:462-466.
- Birks, J; Iakovidou, V; Tsolaki, M. Rivastigmine for Alzheimer's disease. *Cochrane Database Syst Rev* 2000,(2):CD001191.
- Burns A, Rossor M, Hecker J, et al. and the International Donepezil Study Group. The effects of donepezil in Alzheimer's disease: results from a multinational trial. *Dement Geriatr Cogn Disord* 1999;10:237-244.
- Corey-Bloom J, Anand R, Veach J for the ENA 713 B352 Study Group. A randomized trial evaluating the efficacy and safety of ENA 713 rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease. *Int J Geriatr Psychopharmacol* 1998;1:55-65.
- Coyle J; Kershaw P. Galantamine, a cholinesterase inhibitor that allosterically modulates nicotinic receptors: effects on the course of Alzheimer's disease. *Biol Psychiatry* 2001;49:289-99.
- Doody RS, Geldmacher DS, Gordon B, Perdomo CA, Pratt RD. Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. Donepezil Study Group. *Archives of Neurol* 2001;58:427-433.
- Eidelberg D, Dhawan V, Moeller JR, et al. The metabolic landscape of cortico-basal ganglionic degeneration: regional asymmetries studied with positron emission tomography. *J Neurol Neurosurg Psychiatry* 1991;54:856-862.
- Fago, JP. Dementia: causes, evaluation, and management. *Hospital Practice* 2001;36:59-69.
- Farlow M, Anand R, Messina J, Hartman R, Veach J. A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease. *Eur Neurol* 2000;44:236-241.
- Friedland RP, Jagust WJ. Positron and single photon emission tomography in the differential diagnosis of dementia. In: Duara R, ed. *Positron Emission Tomography in Dementia*. New York, N.Y.: Wiley-Liss, Inc; 1990. p. 161-77.
- Galasko D, Hansen LA, Katzman R, et al. Clinical-neuropathological correlations in Alzheimer's disease and related dementias. *Arch Neurol* 1994;51:888-895.
- Gambhir, S.S., Czernin, J., Schwimmer, J., Silverman, D.H.S., Coleman, R.E., Phelps, M.E. A tabulated summary of the FDG PET literature. *J. Nucl. Med.* 2001;42:1S-93S.
- German PS, Shapiro S, Skinner EA, et al. Detection and management of mental health problems of older patients by primary care providers. *JAMA.* 1987;257:489-493.
- Herholz K, Adams R, Kessler J, Szelies B, Grond M, Heiss W-D. Criteria for the diagnosis of Alzheimer's disease with positron emission tomography. *Dementia* 1990;1:156-64.
- Herholz K. FDG PET and differential diagnosis of dementia. *Alzheim Dis and Assoc Disord* 1995;9:6-16.
- Hirono N, Ishii K, Sasaki M, et al. Features of regional cerebral glucose metabolism abnormality in corticobasal degeneration. *Dement Geriatr Cogn Disord* 2000;11:139-146.
- Hoffman JM, Hanson MW, Welsh KA, Earl N, Paine S, DeLong D, Coleman RE. Interpretation variability of 18FDG-positron emission tomography studies in dementia. *Investigative Radiology* 1996;31:316-322.

- Hoffman JM, Welsh-Bohmer K, Hanson M, Crain B, Hulette C, Earl N, Coleman RE. FDG-PET imaging in pathologically verified dementia. *J Nucl Med*, 2000;41:1929-1932.
- Imamura T, Ishii K, Sasaki M, Kitagaki H, Yamaji S, Hirono N, Shimomura T, Hashimoto M, Tanimukai S, Kazui H, Mori E. Regional cerebral glucose metabolism in dementia with Lewy bodies and Alzheimer's disease: a comparative study using positron emission tomography. *Neurosci Lett* 1997;235:49-52.
- Imbimbo BP, Verdelli G, Martelli P, Marchesini D. Two-year treatment of Alzheimer's disease with eptastigmine. *Dement Geriatr Cogn Disord* 1999;10:139-147.
- Ishii K, Sakamoto S, Sasaki M, Kitagaki H, Yamaji S, Hashimoto M, Imamura T, Shimomura T, Hirono N, and Mori E. Cerebral glucose metabolism in patients with frontotemporal dementia. *J Nucl Med* 1998;39:1975-188.
- Knapp MJ, Knopman DS, Solomon PR, Pendlebury WW, Davis CS, Gracon SI. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. The Tacrine Study Group. *JAMA* 1994; 271:985-991.
- Knopman D, Schneider LS, Davis K, et al. Long-term tacrine (Cognex) treatment effects on nursing home placement and mortality. The Tacrine Study Group. *Neurology* 1996; 47:166-177.
- Knopman DS, DeKosky ST, Cummings JL, Chui H, Corey-Bloom J, Relkin N, Small GW, Miller B, and Stevens JC. Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. [see comments]. *Neurology*. 56(9):1143-53, 2001.
- Lim A, Tsuang D, Kukull W, Nochlin D, Leverenz J, McCormick W, Bowen J, Teri L, Thompson J, Peskind ER, Raskind M, Larson EB. Clinico-neuropathological correlation of Alzheimer's disease in a community-based case series. *JAGS* 1999;47:564-9.
- Mayeux R, Saunders AM, Shea S, et al. Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer's disease. *N Eng J Med* 1998; 338: 506-511.
- Mazziotta JC, Phelps ME, Pahl JJ, Huang S-C, Baxter LR, Riege WH, Hoffman JM, Kuhl DE, Lanto AB, Wapenski JA, Markham CH. Reduced cerebral glucose metabolism in asymptomatic subjects at risk for Huntington's disease. *N Engl J Med* 1987;316:357-62.
- Mazziotta JC, Frackowiak RSJ, Phelps ME. The use of positron emission tomography in the clinical assessment of dementia. *Sem Nucl Med* 1992;22:233-46.
- Messa C, Perani D, Lucignani G, Zenorini A, Zito F, Rizzo G, Grassi F, Del Sole A, Franceschi M, Gilardi MC, Fazio F. High-resolution technetium-99m-HMPAO SPECT in patients with probable Alzheimer's disease: comparison with fluorine-18-FDG PET. *J Nucl Med* 1994;35:210-216.
- Mielke R, Schroder R, Fink GR, Kessler J, Herholz K, Heiss WD. Regional cerebral glucose metabolism and postmortem pathology in Alzheimer's disease. *Acta Neuropathol* 1996;91:174-179.
- Mielke R, Heiss W-D. Positron emission tomography for diagnosis of Alzheimer's disease and vascular dementia. *J Neural Transm* 1998;53[Suppl]:237-250.
- Minoshima S, Frey KA, Koeppe RA, Foster NL, Kuhl DE. A diagnostic approach in Alzheimer's disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET. *J Nucl Med* 1995;36:1238-1248.
- Minoshima S, Giordani B, Berent S, Frey KA, Foster NL, and Kuhl DE. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. *Ann Neurol* 1997; 42:85-94.
- Minoshima S, Foster NL, Sima AAF, et al. Alzheimer's disease versus dementia with Lewy bodies: cerebral metabolic distinction with autopsy confirmation. *Ann Neurol* 2001;50:358-365.

Mittelman MS, Ferris SH, Shulman E, Steinberg G, Levin B. A family intervention to delay nursing home placement of patients with Alzheimer's disease. A randomized, controlled trial. *JAMA* 1996; 276:1725-1731.

Morris JC, McKell DW, Storandt M, et al. Very mild Alzheimer's disease: informant-based clinical, psychometric, and pathologic distinction from normal aging. *Neurology* 1991; 41:469-478.

Morris, JC; Cyrus, PA; Orazem, J; Mas, J; Bieber, F; Ruzicka, BB; Gulanski, B. Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease. *Neurology* 1998;50:1222-1230.

Phelps ME. Positron emission tomography provides molecular imaging of biological processes. *Proc Nat Acad Sci.* 2000; 97:9226-9233.

Pietrini P, Alexander GE, Furey ML, Hampel H, Guazzelli M. The neurometabolic landscape of cognitive decline: in vivo studies with positron emission tomography in Alzheimer's disease. *Int J Psychophysiol* 2000;37:87-98.

Raskind MA, Peskind ER, Wessel T, Yuan W, et al. Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. *Neurology* 2000;54:2261-8.

Reiman EM, Caselli RJ, Chen K, Alexander GE, Bandy DJ, Frost JT. Declining brain activity in cognitively normal apolipoprotein E e4 heterozygotes: A foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer's disease. *Proc Natl Acad Sci.* 2001;98:3334-3339.

Reed B, Eberling JL, Mungas D, et al. Frontal lobe hypometabolism predicts cognitive decline in patients with lacunar infarcts. *Arch Neurol* 2001;58:493-497.

Reiman EM, Caselli RJ, Yun LS, Chen K, Bandy D, Minoshima S, Thibodeau SN, Osborne D. Preclinical evidence of Alzheimer's disease in persons homozygous for the $\epsilon 4$ allele for apolipoprotein E. *N Engl J Med* 1996;334:752-8.

Rogers SL, Friedhoff LT. Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: an interim analysis of the results of a US multicentre open label extension Study. *Eur Neuropsychopharmacol* 1998;8:67-75.

Rogers SL, Friedhof LT, Apter JT, et al. The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US multicentre, randomized, double-blind, placebo-controlled trial. *Dementia* 1996;7:293-303.

Rosler M, Anand R, Cicin-Sain A, et al. Efficacy and safety of Rivastigmine in patients with Alzheimer's disease: international randomized controlled trial. *B Med J* 1999;318:633-638.

Ryan DH. Misdiagnosis in dementia: comparisons of diagnostic error rate and range of hospital investigation according to medical specialty. *Int J Geriatr Psychiatry.* 1994; 9:141-147.

Salmon E, Sadzot B, Maquet P, Degueldre C, Lemaire C, Rigo P, et al. Differential diagnosis of Alzheimer's disease with PET. *J Nucl Med* 1994;35:391-398.

Sano M, Ernesto C, Thomas RG, Klauber MR, Schafer K, Grundman, M, Woodbury P, Growdon J, Cotman CW, Pfeiffer E, Schneider LS, Thal LJ. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. *N Engl J Med.* 1997; 336:1216-1222.

Silberstein EB and the Pharmacopeia Committee of the SNM. Prevalence of adverse reactions to positron emitting radiopharmaceuticals in nuclear medicine. *J Nucl Med* 1998; 39:2190-2192.

Silverman DHS, Small GW, Phelps ME. Clinical value of neuroimaging in the diagnosis of dementia: sensitivity and specificity of regional cerebral metabolic and other parameters for early identification of Alzheimer's disease. *Clinical Positron Imaging* 1999; 2:119-130.

Silverman DHS, Small GW, Chang CY, Lu CS, Kung de Aburto MA, Chen W, Czernin J, Rapoport SI, Pietrini P, Alexancer GE, Schapiro MB, Jagust WJ, Hoffman JM, Welsh-Bohmer KA, Alavi A, Clark CM, Salmon E, De Leon MJ, Mielke R, Cummings JL, Kowell AP, Gambhir SS, Hoh CK, Phelps ME. Positron Emission Tomography in the Evaluation of Dementia: Regional brain metabolism and long term outcome. *JAMA* 2001; 286:2120-2127.

Silverman DHS, Gambhir SS, Huang HWC, Schwimmer J, Kim S, Small GW, Chodosh J, Czernin J, Phelps ME. (2002) Evaluating early dementia with and without assessment of regional cerebral metabolism by PET: a comparison of predicted costs and benefits. *J Nucl Med.* 2002; 43:253-266.

Silverman DHS, Truong CT, Kim SK, Chang CY, Chen W, Kowell AP, Cummings JL, Czernin J, Small GW, Phelps ME. Prognostic value of regional cerebral metabolism in patients undergoing dementia evaluation: comparison to a quantifying parameter of subsequent cognitive performance and to prognostic assessment without PET. *Molec Gen and Metab.* 2003; (in press)

Small GW, Rabins PV, Barry PP, Buckholtz NS, DeKosky ST, Ferris SH, Finkel SI, Gwyther LP, Khachaturian ZS, Lebowitz BD, McRae TD, Morris JC, Oakley F, Schneider LS, Streim JE, Sunderland T, Teri LA, Tune LE. Diagnosis and treatment of Alzheimer disease and related disorders: consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer's Association, and the American Geriatrics Society. *JAMA* 1997;278:1363-1371.

Small GW, Mazziotta JC, Collins MT, Baxter LR, Phelps ME, Mandelkern MA, Kaplan A, La Rue A, Adamson CF, Chang L, Guze BH, Corder EH, Saunders AM, Haines JL, Pericak-Vance MA, Roses AD. Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer disease. *JAMA* 1995;273:942-947.

Small GW, Donohue JA, Brooks RL. An economic evaluation of donepezil in the treatment of Alzheimer's disease. *Clinical Therapeutics* 1998;20:838-850.

Small GW, Ercoli LM, Silverman DHS, Huang S-C, Komo S, Bookheimer SY, Lavretsky H, Miller K, Siddarth P, Mazziotta JC, Saxena S, Wu HM, Mega MS, Cummings JL, Saunders AM, Pericak-Vance MA, Roses AD, Barrio JR, Phelps ME. Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease. *Proc Natl Acad Sci USA* 2000;97:6037-6042.

Small GW. Positron emission tomography scanning for the early diagnosis of dementia would improve quality of care for patients and save money. *West J Med* 2000b;171:293-294.

Sultzer DL, Mahler ME, Cummings J, et al. Cortical abnormalities associated with subcortical lesions in vascular dementia. *Arch Neurol* 1995;52:773-780.

Tariot P, Solomon P, Morris J, et al. and the Galantamine Study Group. A 5-month, randomized, placebo-controlled trial of galantamine in AD. *Neurology* 2000;54:2269-2276.

Tedeschi E, Hasselback SG, Waldemar G, et al. Heterogeneous cerebral glucose metabolism in normal pressure hydrocephalus. *J Neurol Neurosurg Psychiatry* 1995;59:608-615.

Turner RS, Kenyon LC, Trojanowski JQ, et al. Clinical, neuroimaging, and pathologic features of progressive nonfluent aphasia. *Ann Neurol* 1996;39:166-173.

U.S. Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research, Recognition and Initial Assessment of Alzheimer's Disease and Related Dementias, Clinical Practice Guideline No. 19, Rockville, 1996.

Vander Borgh T, Minoshima S, Giordani B, Foster NL, Frey KA, Berent S, Albin RL, Koeppe RA, Kuhl DE. Cerebral metabolic differences in Parkinson's and Alzheimer's diseases matched for dementia severity. *J Nucl Med* 1997;38:797-802.

Victoroff J, Mack WJ, Lyness SA, et al. Multicenter clinicopathological correlation in dementia. *Am J Psychiatr* 1995; 152:1476-1484.

Weiner, MF; Martin-Cook, K; Foster, BM; Saine, K; Fontaine, CS; Svetlik, DA. Effects of donepezil on emotional/behavioral symptoms in Alzheimer's disease patients. J Clin Psychiatry 2000;61:487-92.